Online citations, reference lists, and bibliographies.
← Back to Search

Quantitative Analysis Of Senile Plaques In Alzheimer Disease: Observation Of Log-normal Size Distribution And Molecular Epidemiology Of Differences Associated With Apolipoprotein E Genotype And Trisomy 21 (Down Syndrome).

B. Hyman, H. West, G. Rebeck, S. Buldyrev, R. Mantegna, M. Ukleja, S. Havlin, H. Stanley
Published 1995 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
The discovery that the epsilon 4 allele of the apolipoprotein E (apoE) gene is a putative risk factor for Alzheimer disease (AD) in the general population has highlighted the role of genetic influences in this extremely common and disabling illness. It has long been recognized that another genetic abnormality, trisomy 21 (Down syndrome), is associated with early and severe development of AD neuropathological lesions. It remains a challenge, however, to understand how these facts relate to the pathological changes in the brains of AD patients. We used computerized image analysis to examine the size distribution of one of the characteristic neuropathological lesions in AD, deposits of A beta peptide in senile plaques (SPs). Surprisingly, we find that a log-normal distribution fits the SP size distribution quite well, motivating a porous model of SP morphogenesis. We then analyzed SP size distribution curves in genotypically defined subgroups of AD patients. The data demonstrate that both apoE epsilon 4/AD and trisomy 21/AD lead to increased amyloid deposition, but by apparently different mechanisms. The size distribution curve is shifted toward larger plaques in trisomy 21/AD, probably reflecting increased A beta production. In apoE epsilon 4/AD, the size distribution is unchanged but the number of SP is increased compared to apoE epsilon 3, suggesting increased probability of SP initiation. These results demonstrate that subgroups of AD patients defined on the basis of molecular characteristics have quantitatively different neuropathological phenotypes.
This paper references



This paper is referenced by
10.3389/fnagi.2021.719507
Nerve Growth Factor Compromise in Down Syndrome
S. Do Carmo (2021)
10.3233/JAD-201021
Near-Infrared Optical Spectroscopy In Vivo Distinguishes Subjects with Alzheimer’s Disease from Age-Matched Controls
Frank A. Greco (2021)
10.1001/jamaneurol.2021.1649
APOE ε4 Association With Cognition and Alzheimer Disease Biomarkers in Down Syndrome-Implications for Clinical Trials and Treatments for All.
C. Lemere (2021)
10.1016/j.ijbiomac.2021.03.113
The role of amyloid oligomers in neurodegenerative pathologies.
Cameron Wells (2021)
10.3390/jcm10194582
The Clinical and Neuropathological Features of Sporadic (Late-Onset) and Genetic Forms of Alzheimer’s Disease
Tanzil Rujeedawa (2021)
10.1001/jamaneurol.2021.1893
Association of Apolipoprotein E ɛ4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome.
Alexandre Bejanin (2021)
10.1038/s41598-020-68045-8
Assessment of plaque morphology in Alzheimer’s mouse cerebellum using three-dimensional X-ray phase-based virtual histology
L. Massimi (2020)
10.3233/JAD-200134
Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer’s Disease Treated with Escalating Doses for up to 133 Weeks
Heather Guthrie (2020)
10.1016/j.nbd.2020.104784
APOE-amyloid interaction: Therapeutic targets
T. Wisniewski (2020)
10.3389/fnmol.2019.00271
Prionoid Proteins in the Pathogenesis of Neurodegenerative Diseases
Cameron Wells (2019)
10.3233/JAD-190075
LRP::FLAG Rescues Cells from Amyloid-β-Mediated Cytotoxicity Through Increased TERT Levels and Telomerase Activity.
Monique J. Bignoux (2019)
10.1016/j.neulet.2019.134366
Targeting apolipoprotein E for treating Alzheimer’s disease
K. Bales (2019)
10.1055/a-0850-6518
Caveolins; An Assailant or An Ally of Various Cellular Disorders.
R. K. Srivastav (2019)
10.1016/b978-0-12-804766-8.00017-0
Down syndrome.
M. Rafii (2019)
Multimodal visible light optical coherence microscopy for ex vivo brain imaging / submitted by Antonia Lichtenegger, MSc MSc
Antonia Lichtenegger (2019)
BIROn-Birkbeck Institutional Research Online Wiseman, F. and Fisher, E. and Al_Janabi, T. and Hardy, J. and Karmiloff- Smith, Annette and Nizetic, D. and Tybulewicz, V. and Strydom, A. (2015) A genetic cause of Alzheimer disease: mechanistic insights from Down
F. Wiseman (2019)
10.5114/fn.2018.80860
A comparison of the spatial patterns of β-amyloid (Aβ) deposits in five neurodegenerative disorders.
Richard A Armstrong (2018)
10.1201/9781315376875-3
Genetics, Alzheimer’s disease and Down syndrome
N. Schupf (2018)
10.3389/fnagi.2018.00114
Deciphering the Astrocyte Reaction in Alzheimer’s Disease
B. Perez-Nievas (2018)
10.1016/j.freeradbiomed.2017.10.341
Dysregulation of neurotrophin signaling in the pathogenesis of Alzheimer disease and of Alzheimer disease in Down syndrome.
Xu-Qiao Chen (2018)
10.1186/s41231-018-0028-x
Verification of foetal Down syndrome biomarker proteins in maternal plasma and applications in prenatal screening for Down syndrome
W. Sui (2018)
In vivo and in vitro analysis on the effect of LRP/LR on alzheimer's disease related proteins, TERT expression and telomerase activity in alzheimer's disease models
Monique J. Bignoux (2018)
10.1364/BOE.8.004007
Spectroscopic imaging with spectral domain visible light optical coherence microscopy in Alzheimer’s disease brain samples
Antonia Lichtenegger (2017)
10.1523/JNEUROSCI.1698-16.2016
Large Soluble Oligomers of Amyloid β-Protein from Alzheimer Brain Are Far Less Neuroactive Than the Smaller Oligomers to Which They Dissociate
T. Yang (2017)
10.3233/JAD-170164
Quantification of Butyrylcholinesterase Activity as a Sensitive and Specific Biomarker of Alzheimer’s Disease
Ian R. Macdonald (2017)
10.1117/12.2250158
Visible light spectral domain optical coherence microscopy system for ex vivo imaging
Antonia Lichtenegger (2017)
10.1093/BMB/LDW040
Mouse-based genetic modeling and analysis of Down syndrome.
Zhuo Xing (2016)
10.1111/jmi.12446
Biostatistical analysis of quantitative immunofluorescence microscopy images
C. Giles (2016)
10.1016/B978-0-12-804256-4.00004-8
Pathological Consequences of Aβ From Extracellular to Intraneuronal
M. D'Andrea (2016)
10.1038/srep31034
Label-free optical quantification of structural alterations in Alzheimer’s disease
Moosung Lee (2016)
10.1016/S1474-4422(16)00063-6
Dementia in Down's syndrome
C. Ballard (2016)
Defining mechanisms of neurodegeneration associated with protein misfolding diseases
Fiona M. Lane (2015)
See more
Semantic Scholar Logo Some data provided by SemanticScholar